SLC5A2 and type 2 diabetes mellitus: In addition, SGLT-2 inhibitors have benefits on cardiovascular in patients with T2DM, as proven by several key outcomes trials, including VERTIS CV (ertugliflozin) (Rao, 2022), EMPA-REG OUTCOME (empagliflozin), and SCORED (sotagliflozin) (Halimi, 2021).